Abstract 105P
Background
PD-1 blockade has brought impressive response rate in pts with dMMR/MSI-H solid tumors compared with chemotherapy. QL1604, a novel anti-PD-1 antibody, has shown good safety and preliminary anti-tumor activity in advanced solid tumors in the phase I study.
Methods
This single-arm, phase II study (NCT04326829) evaluated the efficacy and safety of QL1604 in pts with unresectable or metastatic dMMR/MSI-H solid tumors from 38 clinical sites across China. Pts received QL1604 (200 mg, iv, Q3W; 3 mg/kg for pts with body weight <40 kg, Q3W), until disease progression, intolerance, withdrawal of consent, or up to 2 years (whichever occurred first). The primary endpoint was objective response rate (ORR) assessed by independent radiological review committee (IRRC) per RECIST 1.1.
Results
From Jun 19, 2020 to Jan 12, 2023, 120 pts with dMMR/MSI-H solid tumors were enrolled, of whom 80 (66.7%) pts had colorectal cancer (CRC), 18 (15.0%) pts had gastric cancer, and 22 (18.3%) had other solid tumors. A total of 97.5% pts had stage IV disease at study entry, and the median prior therapy lines was 2.0 (range, 0-6). With median follow-up of 13.59 mo (range, 0.5–35.3 mo), the ORR and DCR per IRRC were 55/120 (45.8%; 95% CI: 36.7%–55.2%) and 93/120 (77.5%, 95% CI: 69.0%–84.6%), respectively, with 11 (9.2%) complete response (CR) and 44 (36.7%) partial response. In the CRC subgroup, the ORR and DCR per IRRC were 34/80 (42.5%, 95% CI: 31.5%–54.1%) and 62/80 (77.5%, 95% CI: 66.8%–86.1%), respectively. Overall, median duration of response (DoR) was not reached, with 6-mo and 12-mo DoR rates of 100% (95% CI: NE–NE) and 97.4% (95% CI: 83.2%–99.6%), respectively. Median progression-free survival and median overall survival were not reached. TEAEs of any grade occurred in 117 (97.5%) pts. The most frequent treatment-related adverse events (TRAEs) of any grade and grade ≥3 TRAEs were both anemia, with incidence of 25.8% and 5.0%, respectively. No QL1604-related death occurred.
Conclusions
QL1604 showed promising efficacy with high response rate and durable response and tolerable toxicity in pts with dMMR/MSI-H solid tumors.
Clinical trial identification
NCT04326829.
Editorial acknowledgement
Legal entity responsible for the study
Qilu Pharmaceutical Co., Ltd.
Funding
Qilu Pharmaceutical Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
529P - Ramucirumab plus docetaxel after combination chemoimmunotherapy in patients with non-small cell lung cancer: A prospective observational study
Presenter: Tadaaki Yamada
Session: Poster Display
Resources:
Abstract
530P - MYC recruits tumor-associated macrophage to sustain metastatic malignancy of lung adenocarcinoma micropapillary subtype through epigenetic reprogramming
Presenter: Xuming Song
Session: Poster Display
Resources:
Abstract
531P - Effect of combinational targeted therapy for AXL and ATR against malignant mesothelioma cells
Presenter: Soichi Hirai
Session: Poster Display
Resources:
Abstract
532P - The changes of the serum SMRP levels is useful to predict the antitumor efficacy of ipilimumab plus nivolumab combination therapy in patients with malignant pleural mesothelioma
Presenter: Taiichiro Otsuki
Session: Poster Display
Resources:
Abstract
533P - Efficacy in the elderly NSCLC patients in SCORPION study: Phase II study of DTX plus RAM following platinum-based chemotherapy plus ICIs
Presenter: Teppei Yamaguchi
Session: Poster Display
Resources:
Abstract
534P - DSC2 promotes the proliferation, metastasis and drug resistance of lung cancer by activating the PI3K/AKT pathway
Presenter: Qi Li
Session: Poster Display
Resources:
Abstract
535P - Alteration in NKX2-1 CN reshapes the oncogenic, immunologic, and prognostic landscapes in NSCLC
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
536P - The evaluation and long-term outcome of pulmonary metastasectomy for osteosarcoma: A 20-year experience of Shanghai Rujin Hospital
Presenter: Zhusheng Zhang
Session: Poster Display
Resources:
Abstract
537P - The impact of treatment-free interval on patient outcome after pulmonary metastasectomy for sarcoma
Presenter: Po-Kuei Hsu
Session: Poster Display
Resources:
Abstract
538P - First-line chemoimmunotherapy for metastatic thymic carcinoma
Presenter: Victoria Andreas
Session: Poster Display
Resources:
Abstract